Sam Brusco, Associate Editor02.02.24
Intelivation Technologies has launched its Hammerdesis interphalangeal fusion system, in tandem with the American College of Foot and Ankle Surgeons annual meeting taking place this week.
Hammerdesis allows correction of interphalangeal deformities like hammertoes by affixing a distinctively designed ring on the patients toe joint. This implant can save surgeons significant intraoperative time and yield cost savings in the ambulatory surgical center (ASC) setting, according to the company.
Jason R. Miller, DPM, FACFAS of Premier Orthopedics said the peg and hole procedure was clinically proven to be effective, and Hammerdesis is an ideal implant for the procedure.
"I am looking forward to the launch of the Hammerdesis System,” Dr. Miller told the press. “This will not only bring time savings in the OR, but also provide optimal fusion of the joint.
Intelivation’s founder and CEO Rob Anderson added, "Our team is excited to launch the Hammerdesis System. We anticipate outstanding clinical results for patients and look forward to analyzing the early results from our launch sites. This disruptive technology solves intraoperative challenges for surgeons and represents a giant leap forward for the market."
Hammerdesis received U.S. Food and Drug Administration (FDA) clearance in October 2023.
Hammerdesis allows correction of interphalangeal deformities like hammertoes by affixing a distinctively designed ring on the patients toe joint. This implant can save surgeons significant intraoperative time and yield cost savings in the ambulatory surgical center (ASC) setting, according to the company.
Jason R. Miller, DPM, FACFAS of Premier Orthopedics said the peg and hole procedure was clinically proven to be effective, and Hammerdesis is an ideal implant for the procedure.
"I am looking forward to the launch of the Hammerdesis System,” Dr. Miller told the press. “This will not only bring time savings in the OR, but also provide optimal fusion of the joint.
Intelivation’s founder and CEO Rob Anderson added, "Our team is excited to launch the Hammerdesis System. We anticipate outstanding clinical results for patients and look forward to analyzing the early results from our launch sites. This disruptive technology solves intraoperative challenges for surgeons and represents a giant leap forward for the market."
Hammerdesis received U.S. Food and Drug Administration (FDA) clearance in October 2023.